Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502799 · ClinicalTrials.gov registry record · Phase 3
Intervention for Teens With ADHD and Substance Use
A Phase 3 study, sponsored by Florida International University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT02502799: Clinical Trial Phase 3 study, sponsored by Florida International University.
NCT02502799 is a Phase 3 study that was terminated before completion, run by Florida International University. The registered enrollment target is 158 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502799, a Phase 3 study, was terminated before completion, sponsored by Florida International University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use initiation, the goal of this study is to conduct a controlled examination of a brief, early intervention (BEI) for substance modified for adolescents with ADHD. Importantly, this intervention will address individuals who are at risk for problems with substance use, but do not yet meet criteria for severe SUD. Although brief interventions have been found to be effective in other populations, their efficacy in an ADHD population with emerging risk for substance use problems remains uninvestigated. This study aims to understand why some adolescents with ADHD and elevated risk for SUD respond to (BEI) and others do not. The investigators will test whether situational and individual characteristics predict substance use development and response to treatment. Further, this study will assess which types of additional treatment are most effective for youth who do not respond to the initial BEI. It is hypothesized that rates of adolescent substance use will be lower among adolescents who participate in study treatments.
Primary Outcome
Teen self-report of substance use during the past 90 days
Interventions
- DRUG Methylphenidate
- BEHAVIORAL Brief Early Intervention
- BEHAVIORAL Parent Training with Adolescent Cognitive Behavioral Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-07 |
| Est. Completion | 2021-08 |
| Phase | Phase 3 |
Why NCT02502799 stopped before completion
NCT02502799 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 3 interventions - of which Methylphenidate is the first listed.
NCT02502799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02502799 about?
NCT02502799 is a clinical study titled "Intervention for Teens With ADHD and Substance Use". Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use initiation, the goal of this study is to conduct a controlled examination of a b...
What is the current status of trial NCT02502799?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2015-07. Estimated completion is 2021-08.
What interventions are being tested in trial NCT02502799?
The interventions under investigation include: Methylphenidate (DRUG), Brief Early Intervention (BEHAVIORAL), Parent Training with Adolescent Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02502799?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02502799's enrollment target sits among peer trials
158 1502nd of 2000 higher than 496 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia